Insulin detemir is an effective long-acting human insulin analogue for the treatment of type 1 and 2 diabetes mellitus

被引:0
|
作者
不详
机构
关键词
D O I
10.2165/00042310-200521090-00001
中图分类号
学科分类号
摘要
Insulin detemir is a long-acting insulin analogue with slow absorption and a prolonged and consistent metabolic effect. Insulin detemir has a more predictable glucose-lowering effect than insulin suspension isophane (neutral protamine Hagedorn insulin), and less intrapatient variability in glycaemic control than insulin glargine. In comparative trials, insulin detemir was at least as effective as insulin suspension isophane in maintaining glycaemic control and reduced the risk of bodyweight gain in patients with diabetes. Comparative studies with insulin glargine are not yet available. Insulin detemir is as well tolerated as insulin suspension isophane with a similar or lower risk of hypoglycaemia, especially nocturnal hypoglycaemia. © 2005 Adis Data Information BV. All rights reserved.
引用
收藏
页码:1 / 4
页数:3
相关论文
共 50 条
  • [31] Rapid Acting Insulin Analogue Treatment in Children and Adolescents with Type 1 Diabetes Mellitus; Insulin Glulisine Experience
    Ergur, Ayca Torel
    Gunes, Sevinc Odabasi
    [J]. HORMONE RESEARCH IN PAEDIATRICS, 2016, 86 : 253 - 253
  • [32] Evaluation of the effectiveness of long-acting insulin analogs in patients with type 2 diabetes mellitus
    Tuba Taslamacioglu Duman
    Gulali Aktas
    Burcin Meryem Atak Tel
    Satilmis Bilgin
    Gizem Kahveci
    Ozge Kurtkulagi
    [J]. Journal of Public Health, 2023, 31 : 2039 - 2044
  • [33] Pharmacokinetics and -dynamics of therapeutic doses of the "long-acting" insulin analogues glargine and detemir at steady-state in type 1 diabetes mellitus
    Porcellati, F.
    Rossetti, P.
    Busciantella, N. Ricci
    Marzotti, S.
    Lucidi, P.
    Fanelli, C. G.
    Owens, D. R.
    Luzio, S. D.
    Bolli, G. B.
    [J]. DIABETOLOGIA, 2006, 49 : 622 - 623
  • [34] A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
    Chun-Ting Yang
    Kuan-Ying Li
    Chen-Yi Yang
    Huang-Tz Ou
    Shihchen Kuo
    [J]. Scientific Reports, 11
  • [35] A nationwide cohort study for comparative vascular safety of long-acting insulin analogue versus intermediate-acting human insulin in type 2 diabetes
    Yang, Chun-Ting
    Li, Kuan-Ying
    Yang, Chen-Yi
    Ou, Huang-Tz
    Kuo, Shihchen
    [J]. SCIENTIFIC REPORTS, 2021, 11 (01)
  • [36] Insulin detemir versus insulin glargine for type 2 diabetes mellitus
    Simon, A. C. R.
    Swinnen, S. G.
    Holleman, F.
    Hoekstra, J. B. L.
    DeVries, J. H.
    [J]. DIABETOLOGIA, 2011, 54 : S420 - S421
  • [37] Economic evaluation of switching type-1 diabetes patients from long-acting insulin glargine in a basal/bolus regimen to long-acting insulin detemir in an Austrian setting
    Palmer, AJ
    Wittrup-Jensen, KU
    Hansen, JB
    Roze, S
    Valentine, WJ
    [J]. VALUE IN HEALTH, 2005, 8 (06) : A160 - A160
  • [38] Insulin detemir versus insulin glargine for type 2 diabetes mellitus
    Swinnen, Sanne G.
    Simon, Airin C. R.
    Holleman, Frits
    Hoekstra, Joost B.
    DeVries, J. Hans
    [J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2011, (07):
  • [39] PROGRANULIN AND CHEMERIN PLASMA LEVEL IN OBESE PATIENTS WITH TYPE 2 DIABETES TREATED WITH A LONG-ACTING INSULIN ANALOGUE AND PREMIXED INSULIN ANALOGUE
    Waluga-Kozlowska, E.
    Kuznik-Trocha, K.
    Komosinska-Vassev, K.
    Olczyk, P.
    Jura-Poltorak, A.
    Winsz-Szczotka, K.
    Telega, A.
    Ivanova, D.
    Strzoda, W.
    Zimmermann, A.
    Janik, M.
    Olczyk, K.
    Waluga, M.
    [J]. JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2021, 72 (06): : 895 - 903
  • [40] The significance of long acting insulin analogues in the treatment of type 2 diabetes mellitus
    Ludvik, Bernhard
    Brath, Helmut
    Wascher, Thomas
    Toplak, Hermann
    [J]. WIENER KLINISCHE WOCHENSCHRIFT, 2009, 121 (13-14) : 473 - 482